Navin Fluorine shares rally over 5%, hitting all-time high as Q3 PAT jumps 122% YoY; EBITDA surges 109% to ₹308 crore

The company on Monday reported a net profit of ₹185.40 crore for the quarter ended December 31, 2025 (Q3 FY26), registering a sharp rally of 122% against the ₹83.60 crore profit logged in the year-ago period.

Net revenue from operations came in at ₹892.37 crore, up 47% YoY against ₹606.20 crore seen in the year-ago period.

Its operating EBITDA, or operating profit, came in at ₹307.57 crore, up 109% against ₹147.31 crore logged in the corresponding quarter of the previous fiscal year.

EBITDA stands for earnings before interest, taxes, depreciation, and amortisation.

Its operating EBITDA margin surged 1017 bps to 34.5% from 24.3% in the year-ago period.

Segment-wise growth

Its HPP vertical showed a revenue growth of 35%. While Speciality increased by 60%, CDMO revenue surged 60% YoY.

Key highlights

The company’s HPP business vertical reported revenue growth, driven by higher realisations and volumes. The AHF capex project was commissioned in Q4 FY26, with dispatches already commenced. Meanwhile, capex for additional HFC capacity of up to 15,000 MTPA is underway, and the R32 project with a capacity of 15,000 MTPA remains on track for commissioning in Q3 FY27.

The Specialty Chemicals segment delivered its highest-ever quarterly performance, supported by strong order visibility for Q4 and beyond. The product pipeline continues to remain robust, with scale-up in existing molecules and new launches lined up. The Chemours project is progressing as planned and is expected to be completed in Q1 FY27, while debottlenecking of MPP capacity at Dahej is on track for commissioning in Q3 FY27.

The CDMO business vertical maintained strong momentum with healthy order visibility. Under the European CDMO Master Service Agreement (MSA), validation was successfully completed, and commercial supplies have commenced from cGMP4, with a strong outlook into CY26 and beyond.

The company’s strategy of maintaining a balanced portfolio across early- and late-stage molecules continues to deliver results, with supplies concluded for one major EU client and discussions underway for future orders, while scale-up orders for another major EU client are scheduled for Q4 supplies.